DERMALA, a consumer dermatology company developing novel, personalized, microbiome-based solutions for acne and other skin conditions, has closed a $6.73 million Series A financing.

The Series A financing was co-led by Johnson & Johnson Innovation - JJDC, Inc. and True Wealth Ventures. Seventure Partners, investing via their Health for Life Capital Funds, and Cove Fund also joined the financing round.

DERMALA, Inc. is a privately-held consumer dermatology company leveraging scientific understanding of the human microbiome to develop novel solutions for acne and other skin conditions. The company's #FOBO (Fear of Breaking Out) Kit, a personalized microbiome-based solution for acne, combines patent-pending topical acne treatments with oral supplements and a proprietary DERMALA Acne Tracker app that customers use to track their skin health.